10-Q: Athira Pharma Reports Q3 2024 Results, Pauses Fosgonimeton Development

Athira Pharma announced its Q3 2024 results, highlighted by a strategic shift to focus on ATH-1105 development and a workforce reduction, while pausing further development of fosgonimeton.

Summary

• Athira Pharma reported a net loss of $28.7 million for the three months ended September 30, 2024, and a net loss of $81.9 million for the nine months ended September 30, 2024.
• The company's cash, cash equivalents, and investments totaled $68.9 million as of September 30, 2024.
• Research and development expenses decreased to $17.9 million for the three months ended September 30, 2024, and $61.3 million for the nine months ended September 30, 2024, primarily due to decreased spending on the fosgonimeton program.
• A workforce reduction of approximately 70% was initiated in September 2024, expected to result in $2.8 million in costs.
• The company has paused further development of fosgonimeton and is focusing on the clinical development of ATH-1105.
• Athira is exploring strategic alternatives to maximize stockholder value.
• The company estimates its current cash, cash equivalents and investments will be sufficient to fund operations for at least the next 12 months.

Sentiment

Score: 4

Explanation: The document reflects a significant strategic shift and cost-cutting measures due to disappointing clinical trial results, which is generally viewed negatively by investors. However, the company's focus on a new drug candidate and exploration of strategic alternatives provide some hope for the future.

Positives

• The company is focusing on ATH-1105, a novel small molecule drug candidate, which is currently in a Phase 1 clinical trial.
• The company has taken steps to reduce operating costs through a significant workforce reduction.
• The company has sufficient cash, cash equivalents and investments to fund operations for at least the next 12 months.
• The company is exploring strategic alternatives to maximize stockholder value.

Negatives

• The company has paused further development of fosgonimeton after disappointing clinical trial results.
• The company reported a net loss of $81.9 million for the nine months ended September 30, 2024.
• The company has incurred significant losses since its inception and anticipates continuing to incur significant losses for the foreseeable future.
• The company is subject to a Department of Justice investigation, resulting in a $4.1 million legal expense.
• The company has not generated any revenue from drug product sales since inception.

Risks

• The company's ability to generate revenue and achieve profitability depends on the successful development of its drug candidates.
• Clinical development involves a lengthy and expensive process with an uncertain outcome.
• The company may not be successful in identifying and implementing any strategic transaction.
• The company faces significant competition in the biopharmaceutical industry.
• The company is subject to various legal proceedings and government investigations.
• The company's stock price has been and may continue to be volatile.
• The company may not be able to obtain or maintain regulatory approval for its drug candidates.
• The company relies on third parties to conduct its nonclinical studies and clinical trials.
• The company may not be able to obtain adequate market acceptance for its drug candidates, even if approved.
• The company will require substantial additional funding to finance its operations.

Future Outlook

The company estimates its current cash, cash equivalents and investments will be sufficient to fund operations for at least the next 12 months. The company is exploring strategic alternatives to maximize stockholder value and is focusing on the clinical development of ATH-1105.

Management Comments

• The company has paused further development of fosgonimeton and is shifting its focus to the clinical development of ATH-1105.
• The company is exploring strategic alternatives focused on maximizing stockholder value.

Industry Context

The biopharmaceutical industry is characterized by intense competition and high failure rates in drug development. Athira's strategic shift reflects the challenges and uncertainties inherent in bringing new therapies to market, particularly in the field of neurodegenerative diseases. The company's decision to pause fosgonimeton development and focus on ATH-1105 is a common response to clinical trial results that do not meet endpoints.

Comparison to Industry Standards

• The decision to pause development of a drug candidate after Phase 2/3 trial results is not uncommon in the biopharmaceutical industry, as many drug candidates fail to meet endpoints in late-stage trials. For example, Biogen and Eisai's Aduhelm, an Alzheimer's drug, faced significant challenges after its approval, including limited market uptake and questions about its efficacy.
• The workforce reduction of 70% is a significant restructuring, which is not uncommon for companies facing financial challenges or strategic shifts. For example, companies like Sage Therapeutics and Amylyx Pharmaceuticals have also undergone restructuring and layoffs after disappointing clinical trial results or changes in strategic direction.
• The company's cash runway of at least 12 months is typical for clinical-stage biopharmaceutical companies, which often rely on additional funding to support their operations. Companies like Cassava Sciences and Anavex Life Sciences have also raised capital through equity offerings to fund their clinical programs.
• The company's focus on ATH-1105, a small molecule drug candidate, is consistent with the industry trend of developing small molecules for neurodegenerative diseases, as they offer advantages in terms of manufacturing and administration compared to biologics. Companies like AC Immune and Denali Therapeutics are also developing small molecule therapies for neurodegenerative diseases.

Management Changes

Legal Proceedings

• The company is subject to a Department of Justice investigation, resulting in a $4.1 million legal expense.
• The company has settled a securities class action lawsuit for $10.0 million, with an insurance recovery of $1.6 million.
• The company has settled a shareholder derivative action for certain corporate governance reforms and the payment of a fee and expense award to plaintiffs counsel.

Stakeholder Impact

• Shareholders face uncertainty due to the strategic shift and workforce reduction.
• Employees are impacted by the workforce reduction.
• Patients may experience delays in the development of new therapies for neurodegenerative diseases.
• Suppliers and vendors may be affected by the company's cost-cutting measures.

Next Steps

• Complete the Phase 1 clinical trial for ATH-1105 by year-end 2024.
• Begin dosing ALS patients with ATH-1105 in 2025.
• Explore strategic alternatives to maximize stockholder value.
• Continue to optimize the manufacturing process for ATH-1105.

Key Dates

Keywords

ATH-1105, fosgonimeton, clinical trials, neurodegenerative diseases, ALS, Alzheimer's disease, biopharmaceutical, workforce reduction, strategic alternatives, HGF system, intellectual property, regulatory approval